AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00422487
Drug: MBX-2044
RxNorm normalized name: MBX-2044
DrugBank: MBX-2044 (DB05598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-2044 1.5 mg one capsule daily for 14 days
Trial: NCT00422487
Drug: MBX-2044
RxNorm normalized name: MBX-2044
DrugBank: MBX-2044 (DB05598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
Trial: NCT00422487
Drug: MBX-2044
RxNorm normalized name: MBX-2044
DrugBank: MBX-2044 (DB05598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-2044 15 mg one capsule daily for 14 days
Trial: NCT00422487
Drug: MBX-2044
RxNorm normalized name: MBX-2044
DrugBank: MBX-2044 (DB05598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-2044 30 mg two 15 mg capsules daily for 14 days
Trial: NCT00422487
Drug: MBX-2044
RxNorm normalized name: MBX-2044
DrugBank: MBX-2044 (DB05598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-2044 60 mg one capsule daily for 14 days
Trial: NCT00422487
Drug: MBX-2044
RxNorm normalized name: MBX-2044
DrugBank: MBX-2044 (DB05598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
Trial: NCT00422487
Drug: Placebo for MBX-2044
RxNorm normalized name: MBX-2044
DrugBank: MBX-2044 (DB05598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Intervention
Trial: NCT04172220
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-2 mg of Midazolam as premedication.
Trial: NCT00400322
Drug: Valganciclovir (Valcyte)
RxNorm normalized name: valganciclovir Oral Tablet [Valcyte]
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02033941
Drug: Meganatural-Az Grapeseed Extract
RxNorm normalized name: rapeseed sterol extract
DrugBank: Grape (DB10533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
Trial: NCT04720001
Drug: Florbetaben F18
RxNorm normalized name: florbetaben F18
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
Trial: NCT01275300
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01275300
Drug: Niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02040909
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
Trial: NCT03648892
Drug: [c11] raclopride
DrugBank: Raclopride (DB12518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
Trial: NCT03648892
Drug: [18F]fallypride
DrugBank: Fallypride (DB15167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
Trial: NCT00802906
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.5 mg initial intravitreal injection
Trial: NCT02657343
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02657343
Drug: T-DM1
RxNorm normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02657343
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02657343
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00044733
Drug: Mylotarg (gemtuzumab ozogamicin) Injection
RxNorm normalized name: gemtuzumab ozogamicin Injection [Mylotarg]
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02816112
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT02816112
Drug: Neupogen
RxNorm normalized name: Neupogen
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Granulocyte-colony stimulating factor
Trial: NCT03988205
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
Trial: NCT00663260
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 10 mg, Once Daily, 104 weeks
Trial: NCT00663260
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 5 mg, Once Daily, 104 weeks
Trial: NCT03361631
Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination \& Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores \& Pharmaco-Doppler
Trial: NCT04482842
Drug: Warfarin Sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin is administered at a gene-guided dose or at a regular dose.
Trial: NCT01203046
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem 1 gr endovenous 3 or 7 days
Trial: NCT00879398
Drug: Toviaz treatment
RxNorm normalized name: Toviaz
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg starting then can be followed by 8 mg
Trial: NCT01442610
Drug: Rasagiline
RxNorm normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rasagiline tablets 1mg once daily for 8 weeks
Trial: NCT00240019
Drug: Addition of furosemide 20 mg oral bid to baseline regimen
RxNorm normalized name: furosemide 20 MG
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02678377
Drug: OnabotulinumtoxinA (Botox ®) Injections
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
Trial: NCT02678377
Drug: Saline Injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline will be injected into the bladder so that investigators are masked to subject randomization.
Trial: NCT03246880
Drug: Tamsulosin 0.2mg
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: per oral for 12weeks after 2\~4weeks run-in period
Trial: NCT03246880
Drug: Tadalafil 5mg
RxNorm normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: per oral for 12weeks after 2\~4weeks run-in period
Trial: NCT01979185
Drug: SSP-004184SS
RxNorm normalized name: Cercidium floridum ssp. floridum pollen
DrugBank: Parkinsonia florida pollen (DB11006)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00980798
Drug: OROS hydromorphone HCl
RxNorm normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 to 32 mg taken orally once daily for 16 weeks
Trial: NCT02578251
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02578251
Drug: Pethidine
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00319761
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03863574
Drug: Saroglitazar Magnesium 2mg
RxNorm normalized name: pitavastatin magnesium 2 MG
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
Trial: NCT03863574
Drug: Saroglitazar Magnesium 4mg
RxNorm normalized name: pitavastatin magnesium 4 MG
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
Trial: NCT03879798
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
Trial: NCT02607722
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03260322
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous
Trial: NCT02694263
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
Trial: NCT02694263
Drug: Repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
Trial: NCT02694263
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
Trial: NCT02694263
Drug: Gliclazide
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
Trial: NCT02694263
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
Trial: NCT03255473
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
Trial: NCT03255473
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
Trial: NCT02456883
Drug: gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT02456883
Drug: 14C-labeled gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT00417287
Drug: PX-12
RxNorm normalized name: PX-12
DrugBank: PX-12 (DB05448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
Trial: NCT02542215
Drug: Cobiprostone
RxNorm normalized name: Cobiprostone
DrugBank: Cobiprostone (DB05514)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobiprostone 30 mcg oral spray
Trial: NCT00323622
Drug: sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Trial: NCT00323622
Drug: amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Trial: NCT00403052
Drug: 1018 ISS immunostimulatory oligonucleotide
RxNorm normalized name: Exon 53 specific antisense morpholino oligonucleotide
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weekly subcutaneous (under the skin) injections
Trial: NCT01597700
Drug: 10mg Ezetimibe
RxNorm normalized name: ezetimibe 10 MG
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet taken by mouth
Trial: NCT01597700
Drug: 10 mg Ezetimibe - wash out period
RxNorm normalized name: ezetimibe 10 MG
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet taken by mouth received after wash out period
Trial: NCT02024867
Drug: Trimethoprim-Sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 versus 10 days of drug
Trial: NCT00249574
Drug: Buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Human subjects HIV, HCV
Trial: NCT00249574
Drug: pegInterferon
RxNorm normalized name: PEGINTERFERON
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
Trial: NCT04751344
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
Trial: NCT04751344
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
Trial: NCT04053959
Drug: AI assisted insulin system
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients receive the insulin regime set by AI assisted insulin titration system
Trial: NCT04053959
Drug: Physician based insulin regime
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive the insulin regime recommended by physicians
Trial: NCT00072618
Drug: Exisulind
RxNorm normalized name: Exisulind
DrugBank: Exisulind (DB06246)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03110562
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral 100 mg dose
Trial: NCT03110562
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous dose of 1.3 mg/m2
Trial: NCT03110562
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral dose of 20mg
Trial: NCT03366259
Drug: Misoprostol 200Mcg Tab
RxNorm normalized name: MISOPROSTOL 200MCG TAB
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of 200 Mcg of misoprotol rectal
Trial: NCT00515229
Drug: amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch
Trial: NCT04269863
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: control - 81mg. treatment - 81-325mg.
Trial: NCT02248493
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04265274
Drug: Vinorelbin
RxNorm normalized name: Vinorelbin
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2 day 1 and 8,
Trial: NCT02248493
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
Trial: NCT02248493
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
Trial: NCT04265274
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2 day 1
Trial: NCT04265274
Drug: Copper
RxNorm normalized name: Copper
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of elementary Copper daily
Trial: NCT00427258
Drug: MOA-728
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00889330
Drug: alcaftadine
RxNorm normalized name: Alcaftadine
DrugBank: Alcaftadine (DB06766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
Trial: NCT01161966
Drug: Zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide capsules 100 mg
Trial: NCT01161966
Drug: Zonegran
RxNorm normalized name: Zonegran
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonegran Capsules 100 mg of EISAI INC
Trial: NCT00833703
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Trial: NCT02063854
Drug: NE-58095 IR
RxNorm normalized name: Ne
DrugBank: Neon (DB11589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NE-58095 IR tablets
Trial: NCT02063854
Drug: NE-58095 DR
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NE-58095 DR tablets
Trial: NCT03231033
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
Trial: NCT00797303
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
Trial: NCT02705963
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each tablet is 2mg trametinib to be taken orally once daily.
Trial: NCT02705963
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
Trial: NCT02705963
Drug: Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive to be taken orally once daily.